IKT Inhibikase Therapeutics Inc.

4.75
+0.16  (+3%)
Previous Close 4.59
Open 4.61
52 Week Low 4.51
52 Week High 11.8
Market Cap $47,784,283
Shares 10,059,849
Float 4,770,768
Enterprise Value $32,540,188
Volume 5,778
Av. Daily Volume 30,564
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
IkT-148009
Parkinson’s disease
Phase 1
Phase 1
Phase 1 initiation of dosing announced February 17, 2021.

Latest News

  1. ATLANTA, May 17, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders inside and outside of the brain, today reported financial results for the first quarter ended March 31, 2021 and highlighted recent developments.

    Key Business and Clinical Highlights

    • Accelerated timelines for Phase 1 Study of IkT-148009 for the treatment of PD and associated GI Disorders: In February, 2021 Inhibikase commenced patient dosing in its Phase 1 study evaluating the safety, tolerability and pharmacokinetics of IkT-148009, the Company's novel brain penetrant Abelson tyrosine kinase (c-Abl) inhibitor with the potential to modify Parkinson's disease and its gastrointestinal complications. In April, 2021, the Company announced that it had accelerated the timeline for completion of the study based on early data that provided the opportunity to seek regulatory approval to commence dosing of PD patients in the third quarter of 2021, much earlier than previously anticipated.
    • Advancing chronic toxicology studies of IkT-148009 to permit long-term dosing in patients: In January, 2021 Inhibikase initiated 3- and 6-month long-term toxicology studies of IkT-148009 in mice and 3- and 9-month long-term toxicology studies of IkT-148009 in primates as required to obtain regulatory approval for chronic administration of IkT-148009 in patients. The Company has completed 3-month toxicology studies and is presently completing its histopathology analysis in preparation for submission of the data for regulatory review early in the third quarter of 2021. The Company expects to complete 6- and 9-month toxicology studies in the fourth quarter of 2021.
    • Initiated clinical batch manufacturing and pill formulation of IkT-001Pro. In February, 2021, Inhibikase initiated clinical batch manufacturing and final product formulation of IkT-001Pro, the Company's prodrug formulation of Imatinib, designed as a potentially safer, better tolerated treatment for Imatinib-sensitive cancers such as stable-phase Chronic Myeloid Leukemia (CML). Inhibikase expects to file an Investigational New Drug (IND) application in the third quarter of 2021, with initiation of clinical development as soon as practicable after the filing, subject to FDA acceptance of the IND.

    "We are proud of the milestones we have achieved in the first quarter of 2021. The acceleration of our Phase 1 study for our lead candidate, IkT-148009 should allow us to move into evaluation of the safety, tolerability and pharmacokinetics in Parkinson's patients early in the third quarter of 2021. Concurrently, we are advancing two long term toxicology studies in animals, which will allow for chronic administration of IKT-148009 in patients following FDA review and acceptance," commented Milton Werner, Ph.D., President and Chief Executive Officer of Inhibikase. "In the third quarter of 2021, we plan to file our IND application for IKT-001Pro, which holds the potential to be a safer and better tolerated treatment for cancers such as CML, and expect to initiate clinical development as soon as practicable following the submission of the IND application. We look forward to making 2021 a success as we work to advance our early stage programs forward."

    First Quarter Financial Review

    Net Loss: Net loss for the quarter ended March 31, 2021, was $2.6 million, or $0.26 per share, compared to a net loss of $0.5 million, or $0.07 per share for the first quarter in 2020.

    R&D Expenses: Research and development expenses were $2.4 million for the quarter ended March 31, 2021 compared to $0.3 million for the first quarter in 2020. The increase was driven by an increase in grant related research expenditures and non-grant related research. The non-grant related research was expended primarily in connection with the Company's Phase 1 clinical trials.

    SG&A Expenses: Selling, general and administrative expenses for the quarter ended March 31, 2021 were $1.6 million compared to $0.5 million for the first quarter in 2020. The increase was primarily the result of increased non-cash stock compensation expense, increased directors and officer's liability insurance related to the Company's initial public offering in December 2020, increased legal fees, board fees, investor relations and consulting fees relating to operating as a public company registrant since December 2020, and an increase in other normal operating expenses.

    Cash Position: Cash and cash equivalents were $9.6 million as of March 31, 2021.

    About Inhibikase (www.inhibikase.com)

    Inhibikase Therapeutics, Inc. (NASDAQ:IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. Inhibikase is currently performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. The Company is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.

    Social Media Disclaimer

    Investors and others should note that we announce material financial information to our investors using our investor relations website, press releases, SEC filings and public conference calls and webcasts. The company intends to also use Twitter, Facebook, LinkedIn and YouTube as a means of disclosing information about the company, its services and other matters and for complying with its disclosure obligations under Regulation FD.

    Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Inhibikase's current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase's actual results to differ materially from those anticipated by the forward-looking statements. One such uncertainty is that positive results from early clinical studies of our product candidates are not necessarily predictive of the results of later clinical studies and any current and future clinical trials of our product candidates. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth from time to time in Inhibikase's filings with the SEC, including its annual report on Form 10-K filed on March 31, 2021, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

    Inhibikase Therapeutics, Inc.

    Condensed Balance Sheets







    March 31,

    2021





    December 31,

    2020







    (unaudited)









    Assets















    Current assets:















    Cash



    $

    9,609,631





    $

    13,953,513



    Accounts receivable





    332,774









    Prepaid research and development





    712,674







    774,356



    Prepaid expenses and other current assets





    1,216,173







    54,837



    Total





    11,871,252







    14,782,706



    Deferred offering costs





    2,783









    Total assets



    $

    11,874,035





    $

    14,782,706



    Liabilities and stockholders' equity













    Current liabilities:













    Accounts payable



    $

    715,016





    $

    1,720,680



    Accrued expenses and other current liabilities





    627,399







    632,934



    Deferred revenue





    1,251,349







    2,325,741



    Notes payable





    994,789







    42,534



    Total





    3,588,553







    4,721,889



    Notes payable, net of current portion





    248,911







    276,461



    Total liabilities





    3,837,464







    4,998,350



    Commitments and contingencies













    Stockholders' equity:













    Preferred stock, $0.001 par value; 10,000,000 shares authorized at

    March 31, 2021 and December 31, 2020; 0 shares issued and

    outstanding at March 31, 2021 and December 31, 2020.













    Common stock, $0.001 par value; 100,000,000 and 30,000,000

    shares authorized; 10,059,849 and 10,050,849 shares issued and

    outstanding at March 31, 2021 and December 31, 2020, respectively.





    10,060







    10,051



    Additional paid-in capital





    25,695,203







    24,805,929



    Accumulated deficit





    (17,668,692)







    (15,031,624)



    Total





    8,036,571







    9,784,356



    Total liabilities and stockholders' equity



    $

    11,874,035





    $

    14,782,706



     

    Inhibikase Therapeutics, Inc.

    Condensed Statements of Operations

    (Unaudited)







    Three Months Ended March 31,







    2021





    2020



    Revenue:

















    Grant revenue



    $

    1,407,165





    $

    270,787



    Total revenue





    1,407,165







    270,787



    Costs and expenses:

















    Research and development





    2,431,860







    283,114



    Selling, general and administrative





    1,600,576







    527,688



    Total costs and expenses





    4,032,436







    810,802



    Loss from operations





    (2,625,271)







    (540,015)



    Interest expense





    (11,797)







    (7,425)



    Net loss



    $

    (2,637,068)





    $

    (547,440)



    Net loss per share – basic and diluted



    $

    (0.26)





    $

    (0.07)



    Weighted-average number of common shares – basic and diluted





    10,053,949







    8,181,734



     

     

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/inhibikase-therapeutics-reports-first-quarter-2021-financial-results-and-highlights-recent-period-activity-301292776.html

    SOURCE Inhibikase Therapeutics, Inc.

    View Full Article Hide Full Article
  2. ATLANTA, April 21, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders inside and outside of the brain, today announced that Milton Werner, Ph.D., President and Chief Executive Officer, will provide an update on clinical measures of dosing pharmacokinetics and elaborate on IKT-148009's mechanism of action at the Sachs 4th Annual Neuroscience Innovation Forum being held virtually on April 28-30, 2021.

    Dr. Werner will provide a corporate presentation, as well as participate in the Parkinson's & Movement Disorders panel discussion on Wednesday, April 28th, at 1:20 p.m. ET. In addition, Dr. Werner will separately present a corporate overview of Inhibikase.

    About Inhibikase (www.inhibikase.com)

    Inhibikase Therapeutics, Inc. (NASDAQ:IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. Inhibikase is currently performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. The Company is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.

    Social Media Disclaimer

    Investors and others should note that we announce material financial information to our investors using our investor relations website, press releases, SEC filings and public conference calls and webcasts. The company intends to also use Twitter, Facebook, LinkedIn and YouTube as a means of disclosing information about the company, its services and other matters and for complying with its disclosure obligations under Regulation FD.

    Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Inhibikase's current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase's actual results to differ materially from those anticipated by the forward-looking statements. One such uncertainty is that positive results from early clinical studies of our product candidates are not necessarily predictive of the results of later clinical studies and any current and future clinical trials of our product candidates. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth from time to time in Inhibikase's filings with the SEC, including its annual report on Form 10-K filed on March 31, 2021, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum-301273319.html

    SOURCE Inhibikase Therapeutics, Inc.

    View Full Article Hide Full Article
  3. ATLANTA, April 1, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease (PD) and related disorders inside and outside of the brain, today reported financial results for the fourth quarter and full year ended December 31, 2020 and highlighted recent developments.

    Key Business and Clinical Highlights

    • Completed Initial Public Offering: In December 2020, Inhibikase successfully completed its initial public offering (IPO) of 1,800,000 shares of common stock at a public offering price of $10.00 per share. The Company received aggregate net proceeds of approximately $14.60 million after deducting offering costs, underwriting discounts and commissions.



    • Commenced Dosing of Patients in Phase 1 Study of IkT-148009 for the treatment of PD and associated GI Disorders: In February 2021, Inhibikase commenced patient dosing in older and elderly healthy volunteers in a Phase 1 randomized single ascending dose and multiple ascending dose study to determine the safety, tolerability and pharmacokinetics of IkT-148009. IkT-148009 is a novel brain penetrant Abelson tyrosine kinase, or c-Abl, inhibitor intended to be used to modify Parkinson's disease and its gastrointestinal complications.



    • Accelerated timelines for completion of the Phase 1 trial and initiation of dosing in PD patients. Early data from this study have led to a reduction in the timelines for completion of the study by 6 or more months, providing the opportunity to obtain regulatory approval to commence dosing of PD patients much earlier than previously anticipated.



    • Commenced chronic toxicology studies of IkT-148009 to permit long-term dosing in patients. In January, 2021 Inhibikase commenced 3 month and 6 month long-term toxicology studies of IkT-148009 in rats and 3 month and 9 month long-term toxicology studies of IkT-148009 in monkeys as required to obtain regulatory approval for chronic administration of IkT-148009 in patients. These studies are expected to be completed in the fourth quarter of 2021.



    • Commenced clinical batch manufacturing and pill formulation of IkT-001Pro in preparation for an Investigational New Drug application filing in the second quarter of 2021. In February, 2021 Inhibikase commenced clinical batch manufacturing and final product formulation of IkT-001Pro as a film-coated tablet in preparation for regulatory filing with the Food and Drug Administration to initiate clinical development. This regulatory filing is anticipated to be completed near the end of the second quarter of 2021, with initiation of clinical development 30 days after the filing, subject to FDA agreement and issuance of a Study May Proceed notification.

    "2020 was a transformative year for Inhibikase, as we successfully completed our IPO and worked diligently to advance our novel programs to treat neurodegenerative diseases towards the clinic," commented Milton Werner, Ph.D., President and Chief Executive Officer of Inhibikase. "Just recently, we were pleased to announce the advancement of our lead candidate, IkT-148009, into a Phase 1 dose escalation study to evaluate the safety, tolerability and pharmacokinetics in elderly volunteers. Early data from this study has been encouraging and we are shortening the timeline to completion by six or more months, with an expectation to move into early patient studies this year. We believe that IKT-148009 could be a transformative therapy for millions of Parkinson's patients worldwide. Simultaneously, we have advanced our oncology clinical candidate, IkT-001Pro, into manufacturing and expect to initiate clinical development early in the third quarter. Our highly dedicated team has exceeded all of our internal expectations to move these clinical programs forward for the benefit of patients."

    Fourth Quarter and Full Year 2020 Financial Review

    Net Loss: Net loss for the fourth quarter ended December 31, 2020, was $1.21 million, or $0.15 per share, compared to a net loss of $0.43 million, or $0.05 per share for the fourth quarter 2019. For the full year ended December 31, 2020, net loss was $2.85 million, or $0.35 per share, compared to a net loss of $5.72 million, or $0.70 per share, for the same period in 2019.

    R&D Expenses: Research and development expenses were $0.23 million for the fourth quarter 2020, compared to $0.27 million for the same period in 2019. For the full year 2020, research and development expenses were $0.89 million, compared to $2.55 million for the same period in 2019. The decrease was primarily driven by a decline in grant related research expenditures and non-grant related research.

    SG&A Expenses: Selling, general and administrative expenses for the fourth quarter 2020 were $1.14 million compared to $0.39 million for the fourth quarter 2019. For the full year 2020, selling, general and administrative expenses were $2.62 million, compared to $4.27 million for the same period in 2019. The decrease was primarily related to a non-recurring 2019 charge of $1.59 million of deferred IPO costs in connection with the 2018 abandoned IPO effort plus net decrease in all other selling, general and administrative expenses of $0.06 million.

    Cash Position: Cash and cash equivalents were $13.95 million as of December 31, 2020.

    About Inhibikase (www.inhibikase.com)

    Inhibikase Therapeutics, Inc. (NASDAQ:IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. Inhibikase is currently performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. The Company is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.

    Social Media Disclaimer

    Investors and others should note that we announce material financial information to our investors using our investor relations website, press releases, SEC filings and public conference calls and webcasts. The company intends to also use Twitter, Facebook, LinkedIn and YouTube as a means of disclosing information about the company, its services and other matters and for complying with its disclosure obligations under Regulation FD.

    The information we post through these social media channels may be deemed material. Accordingly, we encourage investors and others interested in our company to review the information we make available through these channels. in addition to following the company's press releases, SEC filings and public conference calls and webcasts. This list may be updated from time to time.

    Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Inhibikase's current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase's actual results to differ materially from those anticipated by the forward-looking statements. One such uncertainty is that positive results from early clinical studies of our product candidates are not necessarily predictive of the results of later clinical studies and any current and future clinical trials of our product candidates. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth from time to time in Inhibikase's filings with the SEC, including its annual report on Form 10-K filed on March 31, 2021, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

     

    Inhibikase Therapeutics, Inc.

    Balance Sheets







    December 31,

    2020





    December 31,

    2019



    Assets













    Current assets:













       Cash



    $

    13,953,513





    $

    18,457



       Prepaid research and development





    774,356









       Prepaid expenses and other current assets





    54,837







    16,924



          Total





    14,782,706







    35,381



    Deferred initial public offering costs











    2,873



             Total assets



    $

    14,782,706





    $

    38,254



    Liabilities and stockholders' deficit













    Current liabilities:













       Accounts payable



    $

    1,720,680





    $

    1,001,699



       Accrued expenses and other current liabilities





    632,934







    1,724,141



       Deferred revenue





    2,325,741







    1,428,636



       Notes payable





    42,534







    98,419



          Total





    4,721,889







    4,252,895



       Notes payable, net of current portion





    276,461







    275,375



    Total liabilities





    4,998,350







    4,528,270



    Commitments and contingencies













    Stockholders' equity (deficit):













       Preferred stock, $0.001 par value; 10,000,000 and 0 shares

    authorized at December 31, 2020 and 2019; 0 shares issued and

    outstanding at December 31, 2020 and 2019













       Common stock, $0.001 par value; 100,000,000 and 30,000,000

    shares authorized; 10,050,849 and 8,180,937 shares

    issued and outstanding at December 31, 2020 and 2019





    10,051







    8,181



    Additional paid-in capital





    24,805,929







    7,685,533



    Accumulated deficit





    (15,031,624)







    (12,183,730)



          Total





    9,784,356







    (4,490,016)



             Total liabilities and stockholders' equity (deficit)



    $

    14,782,706





    $

    38,254



     

    Inhibikase Therapeutics, Inc.

    Statements of Operations







    Year ended December 31,







    2020





    2019



    Revenue:

















       Grant revenue



    $

    698,468





    $

    1,122,740



    Total revenue





    698,468







    1,122,740



    Costs and expenses:

















       Research and development





    893,802







    2,552,711



       Selling, general and administrative





    2,623,158







    4,268,177



    Total costs and expenses





    3,516,960







    6,820,888



    Loss from operations





    (2,818,492)







    (5,698,148)



    Interest expense





    (29,402)







    (24,835)



    Net loss



    $

    (2,847,894)





    $

    (5,722,983)



    Net loss per share – basic and diluted



    $

    (0.35)





    $

    (0.70)



    Weighted-average number of common shares – basic and diluted





    8,212,581







    8,180,937



     

    Inhibikase Therapeutics, Inc.

    Statements of Operations







    Quarter ended December 31,







    2020





    2019



    Revenue:

















       Grant revenue



    $

    170,416





    $

    240,276



    Total revenue





    170,416







    240,276



    Costs and expenses:

















       Research and development





    226,944







    267,915



       Selling, general and administrative





    1,144,319







    394,624



    Total costs and expenses





    1,371,263







    662,539



    Loss from operations





    (1,200,847)







    (422,263)



    Interest expense





    (7,139)







    (7,747)



    Net loss



    $

    (1,207,986)





    $

    (430,010)



    Net loss per share – basic and diluted



    $

    (0.15)





    $

    (0.05)



    Weighted-average number of common shares – basic and diluted





    8,286,886







    8,180,937



     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/inhibikase-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and-highlights-recent-period-activity-301260390.html

    SOURCE Inhibikase Therapeutics, Inc.

    View Full Article Hide Full Article
  4. ATLANTA, Mar. 2, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders inside and outside of the brain, today announced that Milton Werner, Ph.D., Chief Executive Officer of Inhibikase, will present at the H.C. Wainwright & Co. Global Life Sciences Virtual Conference.

    The presentation will be available for on-demand viewing under "News & Events" in the Investors section of the Company's website at www.inhibikcase.com, beginning Tuesday, March 9th, 2021 at 7:00 am ET. The webcast will be available for approximately 90 days following the event.

    About Inhibikase (www.inhibikase.com)

    Inhibikase (NASDAQ:IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain. Inhibikase is currently escalating dose in its Phase I, randomized single ascending dose and multiple ascending dose study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/inhibikase-therapeutics-to-present-at-hc-wainwright--co-global-life-sciences-virtual-conference-301238073.html

    SOURCE Inhibikase Therapeutics, Inc.

    View Full Article Hide Full Article
  5. ATLANTA, Feb. 22, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders, today announced that it will present findings from its oral therapy studies for its lead agent IkT-148009 in progressive disease models of Parkinson's at the American Society of Experimental Neurotherapeutics (ASENT) 2021 Annual Meeting, being held virtually from February 22 - 25, 2021.

    Inhibikase's President and Chief Executive Officer, Milton Werner, Ph.D. will describe the benefits observed following therapeutic, oral, daily administration of IkT-148009 in humanized mouse models of slowly progressive Parkinson's disease (PD). These outcomes suggest a mechanistic understanding of the role of alpha-synuclein plaques in the onset of disease.

    Details for the presentation are below:

    Event: American Society of Experimental Neurotherapeutics Conference

    Session: Symposium on Parkinson's Disease: New Approaches

    Presentation Title: Disease modification of Parkinson's Disease through oral kinase inhibitor therapy

    Presentation Date: Thursday, February 25, 2021

    Time: 10:20-10:40am ET

    Following the presentation, there will be a live panel discussion and Q&A session from 11:00-11:15am ET.

    "We are excited to share some of the preclinical results of our IkT-148009 program at the ASENT 2021 conference. C-Abl is believed to be activated by the presence of alpha-synuclein plaque within affected neurons and subsequently, chemically modifies them, which we believe is a key event initiating the disease process in PD," stated Dr. Werner. "We believe that IkT-148009, may have the potential to alter the course of PD and transform the lives of millions of patients worldwide."

    IkT-148009 is intended to be a once daily oral therapy to modify the progression of PD and has demonstrated functional recovery in animal models of Parkinson's disease in the brain and gastrointestinal, or GI, tract, two major organs affected by PD in humans. IkT-148009 is currently in Phase 1 clinical trials for the treatment of PD.

    About Inhibikase (www.inhibikase.com)

    Inhibikase (NASDAQ:IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain. Inhibikase is currently dosing patients in its Phase I, randomized single ascending dose and multiple ascending dose in study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.

    Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements, including statements regarding the closing of the initial public offering and the proceeds of the initial public offering, are based on Inhibikase's current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase's actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Inhibikase's filings with the SEC, including its registration statement on Form S-1, as amended (File No. 333-240036), including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

    Contacts:

    Company Contact:

    Milton H. Werner, PhD

    President & CEO

    678-392-3419

     

    Investor Relations:

    Alex Lobo

    SternIR, Inc.

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/inhibikase-therapeutics-to-present-at-the-american-society-of-experimental-neurotherapeutics-asent-conference-301232095.html

    SOURCE Inhibikase Therapeutics, Inc.

    View Full Article Hide Full Article
View All Inhibikase Therapeutics Inc. News